123 related articles for article (PubMed ID: 27673434)
1. Novel Dimer Compounds That Bind α-Synuclein Can Rescue Cell Growth in a Yeast Model Overexpressing α-Synuclein. A Possible Prevention Strategy for Parkinson's Disease.
Kakish J; Allen KJ; Harkness TA; Krol ES; Lee JS
ACS Chem Neurosci; 2016 Dec; 7(12):1671-1680. PubMed ID: 27673434
[TBL] [Abstract][Full Text] [Related]
2. Drugs That Bind to α-Synuclein: Neuroprotective or Neurotoxic?
Kakish J; Lee D; Lee JS
ACS Chem Neurosci; 2015 Dec; 6(12):1930-40. PubMed ID: 26378986
[TBL] [Abstract][Full Text] [Related]
3. The use of nanopore analysis for discovering drugs which bind to α-synuclein for treatment of Parkinson's disease.
Tavassoly O; Kakish J; Nokhrin S; Dmitriev O; Lee JS
Eur J Med Chem; 2014 Dec; 88():42-54. PubMed ID: 25081642
[TBL] [Abstract][Full Text] [Related]
4. Rasagiline, a suicide inhibitor of monoamine oxidases, binds reversibly to α-synuclein.
Kakish J; Tavassoly O; Lee JS
ACS Chem Neurosci; 2015 Feb; 6(2):347-55. PubMed ID: 25514361
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F
Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431
[TBL] [Abstract][Full Text] [Related]
6. Acetylcorynoline attenuates dopaminergic neuron degeneration and α-synuclein aggregation in animal models of Parkinson's disease.
Fu RH; Wang YC; Chen CS; Tsai RT; Liu SP; Chang WL; Lin HL; Lu CH; Wei JR; Wang ZW; Shyu WC; Lin SZ
Neuropharmacology; 2014 Jul; 82():108-20. PubMed ID: 23973292
[TBL] [Abstract][Full Text] [Related]
7. Cu(II) and dopamine bind to α-synuclein and cause large conformational changes.
Tavassoly O; Nokhrin S; Dmitriev OY; Lee JS
FEBS J; 2014 Jun; 281(12):2738-53. PubMed ID: 24725464
[TBL] [Abstract][Full Text] [Related]
8. Behavior of α-synuclein-drug complexes during nanopore analysis with a superimposed AC field.
Jakova E; Lee JS
Electrophoresis; 2017 Jan; 38(2):350-360. PubMed ID: 27570136
[TBL] [Abstract][Full Text] [Related]
9. Understanding Caffeine's Role in Attenuating the Toxicity of α-Synuclein Aggregates: Implications for Risk of Parkinson's Disease.
Kardani J; Roy I
ACS Chem Neurosci; 2015 Sep; 6(9):1613-25. PubMed ID: 26167732
[TBL] [Abstract][Full Text] [Related]
10. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
11. Yeast-Based Screens to Target Alpha-Synuclein Toxicity.
Brás IC; Popova B; Braus GH; Outeiro TF
Methods Mol Biol; 2019; 1948():145-156. PubMed ID: 30771176
[TBL] [Abstract][Full Text] [Related]
12. Anti-Parkinsonian effects of Bacopa monnieri: insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson's disease.
Jadiya P; Khan A; Sammi SR; Kaur S; Mir SS; Nazir A
Biochem Biophys Res Commun; 2011 Oct; 413(4):605-10. PubMed ID: 21925152
[TBL] [Abstract][Full Text] [Related]
13. Curcumin-glucoside, a novel synthetic derivative of curcumin, inhibits α-synuclein oligomer formation: relevance to Parkinson's disease.
Gadad BS; Subramanya PK; Pullabhatla S; Shantharam IS; Rao KS
Curr Pharm Des; 2012; 18(1):76-84. PubMed ID: 22211690
[TBL] [Abstract][Full Text] [Related]
14. A cell-based model of alpha-synucleinopathy for screening compounds with therapeutic potential of Parkinson's disease.
Zhao DL; Zou LB; Zhou LF; Zhu P; Zhu HB
Acta Pharmacol Sin; 2007 May; 28(5):616-26. PubMed ID: 17439717
[TBL] [Abstract][Full Text] [Related]
15. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
16. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
[TBL] [Abstract][Full Text] [Related]
17. beta-Sheet-breaking peptides inhibit the fibrillation of human alpha-synuclein.
Kim YS; Lim D; Kim JY; Kang SJ; Kim YH; Im H
Biochem Biophys Res Commun; 2009 Oct; 387(4):682-7. PubMed ID: 19622344
[TBL] [Abstract][Full Text] [Related]
18. A novel α-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of α-synuclein-GFP.
Hansen C; Björklund T; Petit GH; Lundblad M; Murmu RP; Brundin P; Li JY
Neurobiol Dis; 2013 Aug; 56():145-55. PubMed ID: 23643841
[TBL] [Abstract][Full Text] [Related]
19. The hexapeptide PGVTAV suppresses neurotoxicity of human α-synuclein aggregates.
Choi MY; Kim YS; Lim D; Kang SJ; Kim YH; Lee K; Im H
Biochem Biophys Res Commun; 2011 May; 408(2):334-8. PubMed ID: 21510923
[TBL] [Abstract][Full Text] [Related]
20. alpha-Synuclein misfolding: single molecule AFM force spectroscopy study.
Yu J; Malkova S; Lyubchenko YL
J Mol Biol; 2008 Dec; 384(4):992-1001. PubMed ID: 18948117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
